CuraTeQ Biologics, a wholly owned unit of Aurobindo Pharma, received Good Manufacturing Practice (GMP) approval from Brazil’s ANVISA on 15 May 2026. The approval covers the Hyderabad plant that produces biosimilar medicines. This milestone is a key step for the company’s global expansion.
The inspection took place from 11 to 15 May 2026 and examined four biosimilar products. It looked at the manufacturing of mammalian and microbial drug substances, the filling of prefillable syringes and vials, and the packaging, labelling, and quality‑control testing facilities.
The Hyderabad site already holds certifications from the European Medicines Agency (EMA) and the World Health Organization (WHO). These approvals confirm that the plant meets international safety and quality standards.
On the stock market, Aurobindo Pharma closed the last trading session at Rs 1,580.45, up Rs 19.90 or 1.28 percent. The share price has reached a 52‑week high of Rs 1,636.00 and a low of Rs 1,017.00, showing strong volatility.
The company’s market capitalisation is currently Rs 91,792.79 crore, reflecting investor confidence in its expanded manufacturing footprint and regulatory approvals.
With the new GMP clearance, Aurobindo Pharma is poised to increase its global biosimilar supply and attract further investment. Investors and industry watchers will keep a close eye on how the company leverages this achievement.